Stockholders' Equity Attributable to Parent in USD of LAVA Therapeutics NV from Q4 2022 to Q3 2025

Taxonomy & unit
us-gaap: USD
Description
Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.
Summary
LAVA Therapeutics NV quarterly Stockholders' Equity Attributable to Parent history and change rate from Q4 2022 to Q3 2025.
  • LAVA Therapeutics NV Stockholders' Equity Attributable to Parent for the quarter ending 30 Sep 2025 was $12,684,000, a 61.6% decline year-over-year.
Stockholders' Equity Attributable to Parent, Quarterly (USD)
Stockholders' Equity Attributable to Parent, YoY Quarterly Change (%)

LAVA Therapeutics NV Quarterly Stockholders' Equity Attributable to Parent (USD)

Period Value YoY Chg Change % Date Report Filed Fiscal Year Fiscal Period
Q3 2025 $12,684,000 -$20,358,000 -61.6% 30 Sep 2025 10-Q 06 Nov 2025 2025 Q3
Q2 2025 $19,935,000 -$22,989,000 -53.6% 30 Jun 2025 10-Q 06 Nov 2025 2025 Q3
Q1 2025 $25,784,000 -$25,028,000 -49.3% 31 Mar 2025 10-Q 06 Nov 2025 2025 Q3
Q4 2024 $27,745,000 -$23,619,000 -46% 31 Dec 2024 10-Q 06 Nov 2025 2025 Q3
Q3 2024 $33,042,000 30 Sep 2024 10-Q 06 Nov 2025 2025 Q3
Q2 2024 $42,924,000 30 Jun 2024 10-Q 06 Nov 2025 2025 Q3
Q1 2024 $50,812,000 31 Mar 2024 10-Q 06 Nov 2025 2025 Q3
Q4 2023 $51,364,000 -$34,757,000 -40.4% 31 Dec 2023 10-Q 06 Nov 2025 2025 Q3
Q4 2022 $86,121,000 31 Dec 2022 10-K 28 Mar 2025 2024 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.